司太立: 司太立2025年半年度报告摘要

Core Viewpoint - Zhejiang Sitaili Pharmaceutical Co., Ltd. reported a 5.06% increase in operating income for the first half of 2025 compared to the same period last year, indicating a positive growth trend in revenue [3]. Financial Performance - Total assets at the end of the reporting period were approximately 5.92 billion yuan, a decrease of 2.03% from the previous year [3]. - Operating income reached approximately 1.40 billion yuan, up 5.06% from approximately 1.33 billion yuan in the same period last year [3]. - Total profit increased by 41.30%, amounting to approximately 39.09 million yuan compared to approximately 27.66 million yuan in the previous year [3]. - Net profit attributable to shareholders was approximately 27.28 million yuan, reflecting a 34.28% increase from approximately 20.32 million yuan in the same period last year [3]. Dividend Distribution - The company plans to distribute a cash dividend of 0.5 yuan per 10 shares to all shareholders, totaling approximately 21.92 million yuan based on the total share capital of 438,409,881 shares as of June 30, 2025 [2]. Shareholder Information - The total number of shareholders at the end of the reporting period was 33,731 [4]. - Major shareholders include Hu Jian (10.56% ownership) and Hu Jingsheng (10.28% ownership), both of whom have pledged a significant portion of their shares [4][5].